?? that's a totally valid question to ask
Case in point, Gilead has a drug that cures Hep C, Sovaldi -- but guess what, if you cure your patients, your pool of patients will eventually dry up
https://www.investors.com/news/techn...ck-abbvie-win/
Trouble is, Gilead didn't just treat hepatitis C. For the most part, it cured patients after about three months ... Eventually, the patient pool was bound to get smaller, and it has. Sovaldi and Harvoni sales fell a respective 24% and 34% in 2016.
...
After climbing rapidly in 2013 and 2014, Gilead stock started to slip in 2015 and lost 31% in 2016 as analysts issued report after report modeling what Gilead would look like without HCV.
Originally Posted by
Jumper Jack
My dude
